REGEN-COV antibody cocktail combinations are recommended for the two patient groups, the updated WHO guideline reported, The BMJ noted.
The first group consists of patients with non-severe COVID-19 with the highest risk of hospitalization. The second group includes seriously or critically patients with coronavirus infection, who are not capable of producing antibodies against COVID-19. At the same time, for other patients, the effect of treatment with the drug proposed by specialists will not be significant.
According to WHO experts, the second recommendation was based on the results of the RECOVERY clinical trial. During it, REGEN-COV reduced the number of deaths and reduced the need for mechanical ventilation in seronegative patients with coronavirus infection.
REGEN-COV is a combination of two monoclonal antibodies, casivirimab and imdevimab, developed by Regeneron Pharmaceuticals. In November, a similar recommendation for the use of a drug previously used in the treatment of President Donald Trump was issued by the US Food and Drug Administration.